On November 15, 2021, we and Valo Health mutually agreed to terminate the proposed initial business combination based on market conditions, particularly in the biotechnology area. As such, we continued to search for a potential initial business combination target thereafter. The PIPE I Investment and PIPE II Investment were also both terminated upon the termination of the proposed initial business combination with Valo Health.
Results of Operations and Known Trends or Future Events
We have neither engaged in any operations (other than searching for a business combination after our IPO) nor generated any revenues to date. Our only activities from January 15, 2021 (inception) through December 31, 2022 were organizational activities and those necessary to prepare for the IPO and the proposed initial business combination. We do not expect to generate any operating revenues until after the completion of our business combination. We expect to generate non-operating income in the form of interest income on marketable securities held after the IPO. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.
For the year ended December 31, 2022, we had a loss from operations of $2,250,380, which consisted of $2,050,380 in general and administrative expenses, and $200,000 in franchise tax expenses, offset by a change in fair value of the Class K founder share derivative liabilities of $150,000, gains on marketable securities (net), dividends and interest, held in the trust account of $5,056,968, income tax expenses of $1,082,963, resulting in a net income of $1,873,625.
For the period from January 15, 2021 (inception) through December 31, 2021, we had a loss from operations of $5,565,939, which consisted of $30,000 in formation costs, $3,986,443 in incomplete Valo Health business combination expenses, $1,349,496 in general and administrative expenses, and $200,000 in franchise tax expenses. We also incurred $12,137,500 in financing expenses on derivative classified instruments, offset by a change in fair value of the Class K founder share derivative liabilities of $12,000,000 and gains on marketable securities (net), dividends and interest, held in the trust account of $17,029, resulting in a net loss of $5,686,410.
Liquidity and Capital Resources
As of December 31, 2022, the Company had $0 in its operating bank account, $350,073,997 in marketable securities held in the trust account to be used for a business combination or to repurchase or redeem its common stock in connection therewith and a working capital deficit of $6,559,542. As of December 31, 2022, $5,056,968 of the amount on deposit in the trust account represented interest income, which is available for payment of income and franchise taxes and other expenses in connection with the liquidation of the trust account.
If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a business combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.
As a result of the above, in connection with the Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the liquidity conditions raise substantial doubt about the Company’s ability to continue as a going concern through approximately one year from the date of filing. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Contractual Obligations
We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.
The underwriters are entitled to a deferred underwriting fee of $0.35 per public share, or $12,075,000 in the aggregate. The deferred underwriting fees will be waived by the underwriters in the event that the Company does not complete a business combination, subject to the terms of the underwriting agreement.
On September 21, 2022, the Company received an executed deferred underwriting fees waiver letter from Goldman Sachs & Co. LLC, informing the Company of its decision to waive any entitlement it may have to its deferred underwriting fees payable held in the Trust Account in respect of any initial business combination. The waiver does not cover deferred underwriting fees payable to Piper Sandler & Co. (representing 10% of the total deferred underwriting fees payable). The waiver is recorded in the Company’s statements of changes in common stock subject to possible redemption and stockholder’s deficit against accumulated deficit.
63